Retatrutide Explained: The Triple GLP-1 / GIP / Glucagon Agonist (Informal "GLP-3" Class)

Retatrutide (Eli Lilly's LY3437943) is an investigational compound that has pushed incretin research past the two-receptor ceiling. Where semaglutide activates a single receptor and tirzepatide activates two, retatrutide is engineered as a single 39-amino-acid peptide that simultaneously agonizes three distinct G-protein-coupled receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). In peptide-research circles it's sometimes shorthanded as the "GLP-3" or "triple-G" class — not a formal pharmacological designation, but a useful way to describe a mechanism that layers a glucagon-driven energy-expenditure pathway on top of the appetite- and insulin-related effects seen with GLP-1 and GIP agonism alone. This article summarizes what the published preclinical and clinical literature says about the molecule itself, strictly as research background. It is not a guide to human use, and it is not a claim about the identity of any product.

What Is Retatrutide (the "GLP-3" Class)?

Structurally, retatrutide is a modified peptide built on a GIP-receptor-agonist backbone, with amino-acid substitutions (including 2-aminoisobutyric acid residues) that confer resistance to DPP-4 degradation and a C20 fatty-diacid moiety that enables reversible albumin binding — the same general design logic used to extend the circulating half-life of other once-weekly incretin peptides. This is the defining feature of the "triple agonist" or informal "GLP-3" class: one molecule engaging three separate receptor systems, dosed once weekly in the clinical-trial protocols published to date. It is currently an investigational compound — it has not been approved by the FDA for any indication — and is in Phase 3 development (the TRIUMPH trial program) for obesity and related metabolic endpoints. Everything discussed here reflects preclinical and clinical-trial literature, not a therapeutic recommendation.

Three Receptors, One Molecule: GLP-1R, GIPR, GCGR

Each receptor retatrutide engages contributes a different piece of metabolic signaling. GLP-1R activation is the mechanism shared with semaglutide and liraglutide: it slows gastric emptying, promotes satiety signaling in the hypothalamus, and enhances glucose-dependent insulin secretion. GIPR activation, the mechanism added in tirzepatide, modulates adipose tissue lipid handling and appears to improve insulin sensitivity while also acting centrally on appetite circuits. GCGR — the glucagon receptor — is the component unique to the triple-agonist class among approved-or-investigational incretin therapies, and it is what principally separates retatrutide's proposed mechanism from dual agonists. Reported in-vitro potency at the three receptors is not equal: published pharmacology places retatrutide as most potent at GIPR, somewhat less potent at GLP-1R, and least potent (though still fully active) at GCGR — a deliberately multi-target profile rather than one receptor dominating alone. Structural biology work using cryo-EM has mapped how a single peptide backbone can adopt receptor-specific binding conformations compatible with all three receptor pockets, which is the basis for describing retatrutide as a genuine triple agonist rather than a mixture of separate ligands (Cell Discovery, 2024).

The Glucagon Component and Energy Expenditure

Glucagon is best known physiologically as insulin's counter-regulatory hormone, raising hepatic glucose output. But GCGR activation also increases hepatic fatty-acid oxidation and, in rodent models, measurably raises energy expenditure — calories burned independent of activity. This is mechanistically distinct from the appetite-suppression and delayed-gastric-emptying effects that drive weight loss with GLP-1-only or GLP-1/GIP dual agonists. In the original preclinical characterization of the molecule, diet-induced obese mice treated with retatrutide lost more weight than mice treated with a GLP-1R/GIPR dual agonist (the tirzepatide mechanism) at comparable exposures, and roughly 30–35% of the additional weight loss was attributed to GCGR-mediated increases in energy expenditure — an effect that was blunted when the glucagon receptor was pharmacologically blocked (Coskun et al., *Cell Metabolism*, 2022). In other words, the preclinical hypothesis is that retatrutide doesn't just make research animals eat less — it appears to make them burn more, a two-lever mechanism that is central to why the molecule generated interest beyond the existing incretin classes. This remains a rodent-model finding; the degree to which the energy-expenditure component contributes to human weight loss is inferred from clinical trial dose-response patterns rather than directly measured in the human trials described below.

Trial Data and the Weight-Loss Hook

The headline human data come from a randomized, placebo-controlled Phase 2 trial in adults with obesity or overweight (Jastreboff et al., *New England Journal of Medicine*, 2023; n=338). Over 48 weeks of dose escalation, the least-squares mean percentage change in body weight was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg), compared with −2.1% on placebo. At the 12 mg dose, 100% of participants achieved at least 5% weight reduction, 93% achieved at least 10%, and 83% achieved at least 15%. A separate Phase 2a trial in participants with metabolic dysfunction-associated steatotic liver disease (MASLD; n=98) reported large reductions in liver fat content — up to roughly 86% at the 12 mg dose over 48 weeks, with the large majority of participants at that dose reaching normal (under 5%) liver fat content — alongside improvements in lipid and glycemic markers (*Nature Medicine*, 2024). These are clinical-trial results in human research participants under IRB-approved protocols with medical supervision — they describe what has been observed in structured trials, not a template for unsupervised use. Longer-duration Phase 3 data are still being reported as the TRIUMPH program completes; those results involve different trial populations and study designs and are not simply an extension of the Phase 2 numbers above.

How It Differs From Single and Dual Agonists

Within the GLP-1R-only class, reported mean weight loss varies substantially by molecule: liraglutide 3.0 mg produced about 8% mean weight loss versus about 3% on placebo over 56 weeks (SCALE, *NEJM* 2015), while once-weekly semaglutide 2.4 mg produced about 15% mean weight loss over 68 weeks (STEP-1, *NEJM* 2021). The dual-agonist class (GLP-1R/GIPR — tirzepatide) improved on that further, with the SURMOUNT-1 trial reporting mean weight loss of roughly 16.0–22.5% across the 5–15 mg dose range over 72 weeks (Jastreboff et al., *NEJM* 2022). The retatrutide Phase 2 data above put its highest studied dose modestly ahead of tirzepatide's highest studied dose over a shorter (48-week) treatment period — up to ~24.2% versus ~22.5% — though the trials differ in duration, population size, and design, so this is a directional comparison across separate studies rather than a head-to-head result. Mechanistically, this progression tracks loosely with receptor count: the working hypothesis in the preclinical literature is that each added receptor target contributes a partially independent lever (appetite suppression, insulin sensitization, energy expenditure) rather than simply duplicating the effect of the receptors already engaged. That hypothesis, more than the topline percentages alone, is why retatrutide is closely watched in metabolic research literature even though it remains investigational and unapproved.

The GLP-3(R) Research Compound

Within the research-peptide supply chain, "GLP-3" has become an informal shorthand some vendors use to label triple-agonist-class research material — it is a nickname referencing the receptor-count concept described above, not a chemical name or a claim of identity to retatrutide or any other specific clinical compound. Any product listed under a name like GLP-3(R) in our catalog should be evaluated on its own COA data, not on the name alone. Before using any lot in a laboratory setting, confirm identity and purity against a current, lot-specific certificate of analysis — see our guide on how to read a COA and our overview of peptide purity standards — and cross-check the lot number through our COA verification tool. Nicknames drive discovery; third-party HPLC data is what actually tells you what's in the vial.

Research Use Only